Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Eureka Therapeutics, Inc.

Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS® T cells
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and Expo
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS® T Cells
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of ET140203 ARTEMIS® T Cells to Treat Pediatric Liver Cancer
From Eureka Therapeutics, Inc.
Via Business Wire
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
From Eureka Therapeutics, Inc.
Via Business Wire
Tickers ASX:IMU
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer
From Eureka Therapeutics, Inc.
Via Business Wire
Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma
From Eureka Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.